Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2021; 9(2): 457-462
Published online Jan 16, 2021. doi: 10.12998/wjcc.v9.i2.457
Paratesticular liposarcoma: Two case reports
Qi-Gang Zheng, Zhao-Hui Sun, Jia-Jian Chen, Jia-Cheng Li, Xiao-Jun Huang
Qi-Gang Zheng, Zhao-Hui Sun, Jia-Jian Chen, Jia-Cheng Li, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310011, Zhejiang Province, China
Xiao-Jun Huang, Department of Urology, The Second Clinical Medical College of Zhejiang Chinese Medical University, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310011, Zhejiang Province, China
Author contributions: Zheng QG and Huang XJ conceived and wrote this report; Zheng QG operated on the patients; Zheng QG, Sun ZH and Li JC organized the data; Huang XJ revised the paper; All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Jun Huang, Doctor, Department of Urology, The Second Clinical Medical College of Zhejiang Chinese Medical University, The Second Affiliated Hospital of Zhejiang Chinese Medical University, No. 318 Chaowang Road, Gongshu District, Hangzhou 310011, Zhejiang Province, China. hxj258111@163.com
Received: August 25, 2020
Peer-review started: August 25, 2020
First decision: October 27, 2020
Revised: October 28, 2020
Accepted: November 13, 2020
Article in press: November 13, 2020
Published online: January 16, 2021
Abstract
BACKGROUND

Paratesticular liposarcoma accounts for approximately 7% of scrotal tumors. They are rare lesions of the reproductive system with approximately 90% of the lesions originating from the spermatic cord. Surgery, with the goal of complete resection, is the mainstay for treatment of this disease. However, treatment consisting of extended resection to decrease local recurrence remains controversial.

CASE SUMMARY

We report the cases of two patients with paratesticular liposarcomas who were treated with radical testicular tumor resection without adjuvant therapy. Follow-up investigations at 9 mo showed no sign of recurrence.

CONCLUSION

Surgery is the first-line treatment, regardless of whether it is a recurrent or primary tumor. Extended resection carries a higher risk of complications and should not be performed routinely. Preoperative radiotherapy can reduce the local recurrence rate without affecting the overall survival.

Keywords: Case report, Paratesticular liposarcoma, Andrology, Radiotherapy, Surgery, Extended resection

Core Tip: Atypical liposarcoma/well-differentiated liposarcoma is commonly distributed in the retroperitoneum, deep tissue of the extremities, and mediastinum, but rarely in the scrotum. We report the cases of two patients with paratesticular liposarcomas who were treated with radical testicular tumor resection without adjuvant therapy. The cases highlight surgery as the first choice of treatment, regardless of primary or recurrent liposarcoma, and show that extended resection is not beneficial for overall survival. Further, radiotherapy can provide a balance between the local recurrence rate and overall survival.